ClinicalTrials.gg
CompletedNCT03629184Updated Apr 29, 2020Results posted

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

A Phase 3 interventional study of Baloxavir Marboxil and Oseltamivir in Influenza, sponsored by Hoffmann-La Roche. Completed at 37 sites in 7 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
15th of 18
173 · median 483
Started
2018
the only one that year
Phase 3
12 of 18
5 open now
Registered
4th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 15th largest by enrollment, is the only one that started in 2018, is one of 12 in phase 3, and was the 4th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to \<12 years of age) with influenza-like symptoms.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 1 to \< 12 years at randomization (Day 1).
  • Written /assent for study participation obtained from participant's parents or legal guardian, with assent as appropriate by the participant, depending on the patient's level of understanding
  • Participant able to comply with study requirements, depending on the patient's level of understanding
  • Participant with a diagnosis of influenza virus infection confirmed by the presence of all of the following:
  • Fever ≥ 38 degree celsius (tympanic temperature) at screening
  • At least one respiratory symptom (either cough or nasal congestion)
  • The time interval between the onset of symptoms and screening is ≤ 48 hours

Exclusion criteria

Exclusion Criteria:

  • Severe symptoms of influenza virus infection requiring inpatient treatment
  • Concurrent infections requiring systemic antiviral therapy at screening
  • Require, in the opinion of the investigator, any of the prohibited medication during the study
  • Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening
  • Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to randomization
  • Concomitant treatment with or other immuno-suppressant therapy
  • Known infection or other disorder
  • Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure.
  • Active cancer at any site
  • History of organ transplantation
  • Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to acetaminophen
  • Females with
  • Participation in a clinical trial within 4 weeks or five half-lives of exposure to an drug prior to screening, whichever is longer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.

    Drug: Baloxavir Marboxil

  • Active comparator
    Oseltamivir

    Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1

    Drug: Oseltamivir

Interventions

  • Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1. Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.

  • Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

    Time frame: Up to Day 29

Secondary outcomes

  1. Plasma Concentrations of Baloxavir Marboxil - Sparse PK Population

    Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

    Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10

  2. Plasma Concentrations of S-033447 - Sparse PK Population

    Results provided by body-weight groups for participants in the Baloxavir Marboxil arm.

    Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10

  3. Plasma Concentrations of Baloxavir Marboxil - Extensive PK Population

    Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

    Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10

  4. Plasma Concentrations of S-033447 - Extensive PK Population

    Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

    Time frame: Days 1 (Post-Dose), 2, 4, 6 and 10

  5. Time to Alleviation of Influenza Signs and Symptoms

    Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met and remain so for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]) * A "yes" response to the following question on the CARIFS: "Since the last assessment has the subject been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?" * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\])

    Time frame: Up to Day 15

  6. Duration of Fever

    Length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours.

    Time frame: Up to Day 15

  7. Duration of Symptoms

    The clinical efficacy of baloxavir marboxil is evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire.

    Time frame: Up to Day 15

  8. Time to Return to Normal Health and Activity

    Time to Return to Normal health and activity' is identified by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"

    Time frame: Up to Day 15

  9. Frequency of Influenza-Related Complications

    Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.

    Time frame: Up to Day 29

  10. Percentage of Participants With Influenza-Related Complications

    Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.

    Time frame: Up to Day 29

  11. Percentage of Participants Requiring Antibiotics

    Time frame: Up to Day 29

  12. Time to Cessation of Viral Shedding by Virus Titer

    Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer is below the limit of detection.

    Time frame: Day 1 - Day 29

  13. Time to Cessation of Viral Shedding by RT-PCR

    Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of any study treatment and first time when the virus RNA by RT-PCR is below the limit of detection.

    Time frame: Day 1 - Day 29

  14. Change From Baseline in Influenza Virus Titer at Day 2, 4, 6, 10, 15, 29

    Influenza virus titer (log10TCID50/ML) is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.

    Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29

  15. Change From Baseline in the Amount of Virus RNA (RT-PCR) at Day 2, 4, 6, 10, 15, 29

    If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

    Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29

  16. Percentage of Participants With Positive Influenza Virus Titer at Day 2, 4, 6, 10

    Time frame: Baseline, Day 2, 3 (optional), 4, 6, 10

  17. Percentage of Participants Positive by RT-PCR at Day 2, 4, 6, 10, 15, 29

    Time frame: Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29

  18. Area Under the Curve in Virus Titer

    Area under the curve (AUC) in virus titer was calculated using the trapezoidal method.

    Time frame: Day 1 - Day 29

  19. Area Under the Curve in the Amount of Virus RNA (RT-PCR)

    AUC in virus RNA (RT-PCR) is defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 10. AUC is calculated using the trapezoidal method similar to AUC in virus titer.

    Time frame: Day 1 - Day 10

  20. Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  21. Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of S-033447.

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  22. Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  23. Maximum Plasma Concentration (Cmax) of S-033447

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  24. Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  25. Time to Maximum Plasma Concentration (Tmax) of S-033447

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: Up to Day 10

  26. Plasma Concentrations of Baloxavir Marboxil by Dosage

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: 24, 72, 96 and 240 hours post-dose

  27. Plasma Concentrations of S-033447 by Dosage

    Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

    Time frame: 24, 72, 96 and 240 hours post-dose

07

Results

Posted Apr 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneBaloxavir MarboxilOseltamivir
Started11558
Completed11257
Not completed31
Withdrew: Withdrawal by subject21
Withdrew: Physician decision10

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsBaloxavir MarboxilOseltamivir
Adverse Events (AEs)46.153.4
Serious Adverse Events (SAEs)00
SecondaryPlasma Concentrations of Baloxavir Marboxil - Sparse PK Population

Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

Time frame:
Days 1 (Post-Dose), 2, 4, 6 and 10
Reported as:
Mean · ng/mL
Plasma Concentrations of Baloxavir Marboxil - Sparse PK Population
ng/mLBaloxavir Marboxil
5 - <10 kg (Day 1)0.000 ± NA
5 - <10 kg (Day 2)0.000 ± NA
5 - <10 kg (Day 6)0.000 ± NA
10 - <15 kg (Day 1)0.073 ± 0.2001
10 - <15 kg (Day 2)0.000 ± 0.0000
10 - <15 kg (Day 4)0.000 ± 0.0000
10 - <15 kg (Day 6)0.000 ± 0.0000
10 - <15 kg (Day 10)0.000 ± 0.0000
15 - <20 kg (Day 1)0.090 ± 0.2386
15 - <20 kg (Day 2)0.000 ± 0.0000
15 - <20 kg (Day 4)0.000 ± 0.0000
15 - <20 kg (Day 6)0.000 ± 0.0000
15 - <20 kg (Day 10)0.000 ± 0.0000
>=20 kg (Day 1)0.048 ± 0.1936
>=20 kg (Day 2)0.000 ± 0.0000
>=20 kg (Day 4)0.000 ± 0.0000
>=20 kg (Day 6)0.000 ± 0.0000
>=20 kg (Day 10)0.000 ± 0.0000
SecondaryPlasma Concentrations of S-033447 - Sparse PK Population

Results provided by body-weight groups for participants in the Baloxavir Marboxil arm.

Time frame:
Days 1 (Post-Dose), 2, 4, 6 and 10
Reported as:
Mean · ng/mL
Plasma Concentrations of S-033447 - Sparse PK Population
ng/mLBaloxavir Marboxil
5 - <10 kg (Day 1)45.700 ± NA
5 - <10 kg (Day 2)45.800 ± NA
5 - <10 kg (Day 6)3.110 ± NA
10 - <15 kg (Day 1)49.084 ± 53.6689
10 - <15 kg (Day 2)42.900 ± 16.5227
10 - <15 kg (Day 4)9.233 ± 5.3879
10 - <15 kg (Day 6)2.965 ± 1.6480
10 - <15 kg (Day 10)0.367 ± 0.6351
15 - <20 kg (Day 1)64.160 ± 73.6320
15 - <20 kg (Day 2)67.729 ± 46.7346
15 - <20 kg (Day 4)15.840 ± 10.8285
15 - <20 kg (Day 6)4.829 ± 3.6562
15 - <20 kg (Day 10)1.110 ± 1.9226
>=20 kg (Day 1)29.899 ± 26.1558
>=20 kg (Day 2)56.287 ± 40.4073
>=20 kg (Day 4)18.674 ± 11.2179
>=20 kg (Day 6)7.397 ± 5.0530
>=20 kg (Day 10)3.953 ± 2.2536
SecondaryPlasma Concentrations of Baloxavir Marboxil - Extensive PK Population

Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

Time frame:
Days 1 (Post-Dose), 2, 4, 6 and 10
Reported as:
Mean · ng/mL
Plasma Concentrations of Baloxavir Marboxil - Extensive PK Population
ng/mLBaloxavir Marboxil
Day 1, 0.5 - 2 hrs (10 - <15 kg)0.000 ± 0.0000
Day 1, 4 hrs (10 - <15 kg)0.000 ± 0.0000
Day 1, 6 hrs (10 - <15 kg)0.000 ± NA
Day 2 (10 - <15 kg)0.000 ± 0.0000
Day 4 (10 - <15 kg)0.000 ± NA
Day 6 (10 - <15 kg)0.000 ± 0.0000
Day 10 (10 - <15 kg )0.000 ± NA
Day 1, 0.5 - 2 hrs (15 - <20 kg)0.000 ± 0.0000
Day 1, 4 hrs (15 - <20 kg)0.000 ± NA
Day 1, 6 hrs (15 - <20 kg)0.000 ± NA
Day 2 (15 - <20 kg)0.000 ± 0.0000
Day 4 (15 - <20 kg)0.000 ± NA
Day 6 (15 - <20 kg)0.000 ± 0.0000
Day 1, 0.5 - 2 hrs (>=20 kg)0.051 ± 0.1600
Day 1, 4 hrs (>=20 kg)0.062 ± 0.1863
Day 1, 6 hrs ((>=20 kg)0.000 ± 0.0000
Day 2 (>=20 kg)0.000 ± 0.0000
Day 4 (>=20 kg)0.000 ± 0.0000
Day 6 (>=20 kg)0.000 ± 0.0000
SecondaryPlasma Concentrations of S-033447 - Extensive PK Population

Results provided by body-weight groups for participants in the Baloxavir Marboxil arm. Values below lower limit of quantification (0.5 ng/mL) are set to zero.

Time frame:
Days 1 (Post-Dose), 2, 4, 6 and 10
Reported as:
Mean · ng/mL
Plasma Concentrations of S-033447 - Extensive PK Population
ng/mLBaloxavir Marboxil
Day 1, 0.5 - 2 hrs (10 - <15 kg)10.768 ± 14.7987
Day 1, 4 hrs (10 - <15 kg)49.500 ± 13.0108
Day 1, 6 hrs (10 - <15 kg)41.000 ± NA
Day 2 (10 - <15 kg)28.933 ± 14.7514
Day 4 (10 - <15 kg)2.230 ± NA
Day 6 (10 - <15 kg)3.131 ± 2.2828
Day 10 (10 - <15 kg )0.000 ± NA
Day 1, 0.5 - 2 hrs (15 - <20 kg)93.883 ± 152.5431
Day 1, 4 hrs (15 - <20 kg)72.900 ± NA
Day 1, 6 hrs (15 - <20 kg)80.300 ± NA
Day 2 (15 - <20 kg)42.640 ± 47.6024
Day 4 (15 - <20 kg)12.200 ± NA
Day 6 (15 - <20 kg)2.663 ± 1.5387
Day 1, 0.5 - 2 hrs (>=20 kg)19.923 ± 27.0980
Day 1, 4 hrs (>=20 kg)69.198 ± 55.7220
Day 1, 6 hrs ((>=20 kg)65.527 ± 43.0799
Day 2 (>=20 kg)57.980 ± 37.8922
Day 4 (>=20 kg)21.775 ± 3.7968
Day 6 (>=20 kg)6.240 ± 3.3702
SecondaryTime to Alleviation of Influenza Signs and Symptoms

Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met and remain so for at least 21.5 hours: * A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale \[CARIFS\]) * A "yes" response to the following question on the CARIFS: "Since the last assessment has the subject been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?" * First return to afebrile state (tympanic temperature ≤37.2 degree Celsius \[°C\])

Time frame:
Up to Day 15
Reported as:
Median · hours
Time to Alleviation of Influenza Signs and Symptoms
hoursBaloxavir MarboxilOseltamivir
Time to Alleviation of Influenza Signs and Symptoms138.1 (116.6 to 163.2)150.0 (115.0 to 165.7)
SecondaryDuration of Fever

Length of time taken by participants to return to afebrile state \[tympanic temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours.

Time frame:
Up to Day 15
Reported as:
Median · hours
Duration of Fever
hoursBaloxavir MarboxilOseltamivir
Duration of Fever41.2 (24.5 to 45.7)46.8 (30.0 to 53.5)
SecondaryDuration of Symptoms

The clinical efficacy of baloxavir marboxil is evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 \[no problem\] or 1 \[minor problem\] and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire.

Time frame:
Up to Day 15
Reported as:
Median · hours
Duration of Symptoms
hoursBaloxavir MarboxilOseltamivir
Duration of Symptoms66.4 (43.7 to 76.4)67.9 (45.8 to 88.7)
SecondaryTime to Return to Normal Health and Activity

Time to Return to Normal health and activity' is identified by a 'Yes' response to the following question on the CARIFS: "Since the last assessment has the patient been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?"

Time frame:
Up to Day 15
Reported as:
Median · hours
Time to Return to Normal Health and Activity
hoursBaloxavir MarboxilOseltamivir
Time to Return to Normal Health and Activity116.5 (94.9 to 138.0)111.6 (80.8 to 138.3)
SecondaryFrequency of Influenza-Related Complications

Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.

Time frame:
Up to Day 29
Reported as:
Number · count of events
Frequency of Influenza-Related Complications
count of eventsBaloxavir MarboxilOseltamivir
Total64
Death00
Hospitalization00
Sinusitis10
Otitis Media33
Pneumonia10
Bronchitis10
Encephalitis/Encephalopathy00
Febrile Seizures01
Myositis00
SecondaryPercentage of Participants With Influenza-Related Complications

Influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.

Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Influenza-Related Complications
percentage of participantsBaloxavir MarboxilOseltamivir
Total7.47.0
Death00
Hospitalization00
Sinusitis1.20
Otitis Media3.74.7
Pneumonia1.20
Bronchitis1.20
Encephalitis/Encephalopathy00
Febrile Seizures02.3
Myositis00
SecondaryPercentage of Participants Requiring Antibiotics
Time frame:
Up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Antibiotics
percentage of participantsBaloxavir MarboxilOseltamivir
Total4.94.7
Bronchitis00
Otitis Media2.54.7
Pneumonia1.20
Sinusitis1.20
SecondaryTime to Cessation of Viral Shedding by Virus Titer

Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of any study treatment and first time when the influenza virus titer is below the limit of detection.

Time frame:
Day 1 - Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Virus Titer
hoursBaloxavir MarboxilOseltamivir
Time to Cessation of Viral Shedding by Virus Titer24.2 (23.5 to 24.6)75.8 (68.9 to 97.8)
SecondaryTime to Cessation of Viral Shedding by RT-PCR

Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of any study treatment and first time when the virus RNA by RT-PCR is below the limit of detection.

Time frame:
Day 1 - Day 29
Reported as:
Median · hours
Time to Cessation of Viral Shedding by RT-PCR
hoursBaloxavir MarboxilOseltamivir
Time to Cessation of Viral Shedding by RT-PCR242.5 (235.8 to 262.8)238.9 (214.0 to 286.7)
SecondaryChange From Baseline in Influenza Virus Titer at Day 2, 4, 6, 10, 15, 29

Influenza virus titer (log10TCID50/ML) is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.

Time frame:
Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Reported as:
Mean · log10TCID50/ML
Change From Baseline in Influenza Virus Titer at Day 2, 4, 6, 10, 15, 29
log10TCID50/MLBaloxavir MarboxilOseltamivir
Baseline4.43 ± 1.364.27 ± 1.48
Day 2-3.59 ± 1.34-1.79 ± 1.54
Day 3 (optional visit)-2.83 ± 0.58-2.63 ± 0.88
Day 4-3.53 ± 1.38-3.27 ± 1.54
Day 6-3.55 ± 1.32-3.52 ± 1.50
Day 10-3.66 ± 1.40-3.50 ± 1.42
Day 15 (optional visit)-3.75 ± 0.54-3.63 ± 1.45
Day 29-3.50 ± 1.43-3.75 ± 1.19
SecondaryChange From Baseline in the Amount of Virus RNA (RT-PCR) at Day 2, 4, 6, 10, 15, 29

If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

Time frame:
Baseline, Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Reported as:
Mean · log10 virus particles/mL
Change From Baseline in the Amount of Virus RNA (RT-PCR) at Day 2, 4, 6, 10, 15, 29
log10 virus particles/mLBaloxavir MarboxilOseltamivir
Baseline6.46 ± 1.506.86 ± 1.02
Day 2-1.74 ± 1.13-1.12 ± 1.12
Day 3 (optional)-1.78 ± 1.50-2.21 ± 0.94
Day 4-2.40 ± 1.50-2.47 ± 1.35
Day 6-2.73 ± 1.78-3.32 ± 1.27
Day 10-3.55 ± 1.62-3.81 ± 1.19
Day 15 (optional)-1.24 ± 3.06-4.44 ± NA
Day 292.18 ± NA—
SecondaryPercentage of Participants With Positive Influenza Virus Titer at Day 2, 4, 6, 10
Time frame:
Baseline, Day 2, 3 (optional), 4, 6, 10
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer at Day 2, 4, 6, 10
percentage of participantsBaloxavir MarboxilOseltamivir
Baseline100100
Day 215.675.7
Day 3 (optional)33.350.0
Day 426.229.0
Day 612.75.7
Day 101.60
SecondaryPercentage of Participants Positive by RT-PCR at Day 2, 4, 6, 10, 15, 29
Time frame:
Day 2, 3 (optional), 4, 6, 10, 15 (optional), 29
Reported as:
Number · percentage of participants
Percentage of Participants Positive by RT-PCR at Day 2, 4, 6, 10, 15, 29
percentage of participantsBaloxavir MarboxilOseltamivir
Baseline100100
Day 295.9100
Day 3 (optional)100100
Day 489.997.0
Day 683.175.7
Day 1046.544.1
Day 15 (optional)40.025.0
Day 2925.00
SecondaryArea Under the Curve in Virus Titer

Area under the curve (AUC) in virus titer was calculated using the trapezoidal method.

Time frame:
Day 1 - Day 29
Reported as:
Mean · log₁₀[TCID₅₀/mL]*hours
Area Under the Curve in Virus Titer
log₁₀[TCID₅₀/mL]*hoursBaloxavir MarboxilOseltamivir
Area Under the Curve in Virus Titer-863.81 ± 543.37-849.29 ± 684.43
SecondaryArea Under the Curve in the Amount of Virus RNA (RT-PCR)

AUC in virus RNA (RT-PCR) is defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 10. AUC is calculated using the trapezoidal method similar to AUC in virus titer.

Time frame:
Day 1 - Day 10
Reported as:
Mean · log₁₀ VPs/mL*hours
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
log₁₀ VPs/mL*hoursBaloxavir MarboxilOseltamivir
Area Under the Curve in the Amount of Virus RNA (RT-PCR)-381.53 ± 338.53-353.31 ± 304.01
SecondaryArea Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · ng.hr/mL
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of Baloxavir Marboxil
ng.hr/mLBaloxavir Marboxil
Non-Asian - 2 mg/kgNA ± NA
Asian - 40 mgNA ± NA
Non-Asian - 40 mgNA ± NA
SecondaryArea Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of S-033447.

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · ng.hr/mL
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf) of S-033447.
ng.hr/mLBaloxavir Marboxil
Non-Asian - 2 mg/kg4050 ± 2080
Asian - 40 mg6600 ± NA
Non-Asian - 40 mg4390 ± 2080
SecondaryMaximum Plasma Concentration (Cmax) of Baloxavir Marboxil

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Baloxavir Marboxil
ng/mLBaloxavir Marboxil
Non-Asian - 2 mg/kgNA ± NA
Asian - 40 mgNA ± NA
Non-Asian - 40 mgNA ± NA
SecondaryMaximum Plasma Concentration (Cmax) of S-033447

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of S-033447
ng/mLBaloxavir Marboxil
Non-Asian - 2 mg/kg109 ± 55.3
Asian - 40 mg110 ± NA
Non-Asian - 40 mg83.2 ± 36.5
SecondaryTime to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax) of Baloxavir Marboxil
hoursBaloxavir Marboxil
Non-Asian - 2 mg/kgNA ± NA
Asian - 40 mgNA ± NA
Non-Asian - 40 mgNA ± NA
SecondaryTime to Maximum Plasma Concentration (Tmax) of S-033447

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
Up to Day 10
Reported as:
Mean · hours
Time to Maximum Plasma Concentration (Tmax) of S-033447
hoursBaloxavir Marboxil
Non-Asian - 2 mg/kg4.12 ± 2.07
Asian - 40 mg5.50 ± NA
Non-Asian - 40 mg5.55 ± 3.79
SecondaryPlasma Concentrations of Baloxavir Marboxil by Dosage

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
24, 72, 96 and 240 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Baloxavir Marboxil by Dosage
ng/mLBaloxavir Marboxil
24 - Non-Asian - 2 mg/kgNA ± NA
24 - Asian - 40 mgNA ± NA
24 - Non-Asian - 40 mgNA ± NA
72 - Non-Asian - 2 mg/kgNA ± NA
72 - Asian - 40 mgNA ± NA
72 - Non-Asian - 40 mgNA ± NA
96 - Non-Asian - 2 mg/kgNA ± NA
96 - Asian - 40 mgNA ± NA
96 - Non-Asian - 40 mgNA ± NA
240 - Non-Asian - 2 mg/kgNA ± NA
240 - Asian - 40 mgNA ± NA
240 - Non-Asian - 40 mgNA ± NA
SecondaryPlasma Concentrations of S-033447 by Dosage

Dose groups correspond to body-weight groups. 2mg/kg dose was used for subjects \<20 kgs and 40 mg dose was used for subjects \>20 kgs.

Time frame:
24, 72, 96 and 240 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of S-033447 by Dosage
ng/mLBaloxavir Marboxil
24 - Non-Asian - 2 mg/kg55.7 ± 28.1
24 - Asian - 40 mg75.2 ± NA
24 - Non-Asian - 40 mg53.2 ± 22.4
72 - Non-Asian - 2 mg/kg13.2 ± 7.15
72 - Asian - 40 mg28.9 ± NA
72 - Non-Asian - 40 mg17.90 ± 8.910
96 - Non-Asian - 2 mg/kg7.61 ± 4.400
96 - Asian - 40 mg19.0 ± NA
96 - Non-Asian - 40 mg11.3 ± 6.160
240 - Non-Asian - 2 mg/kg0.989 ± 0.887
240 - Asian - 40 mg3.31 ± NA
240 - Non-Asian - 40 mg1.85 ± 1.400

Adverse events

Collected over From baseline (Day 1) until 28 days after the last dose of study drug (29 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil0/115 (0%)0/115 (0%)15/115 (13%)
Oseltamivir0/58 (0%)0/58 (0%)13/58 (22.4%)
Most frequent other events
Most frequent other events
EventBaloxavir MarboxilOseltamivir
VomitingGastrointestinal disorders7/1159/58
Otitis MediaInfections and infestations3/1154/58
DiarrhoeaGastrointestinal disorders6/1151/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)Baloxavir MarboxilOseltamivirTotal
Mean6.10 ± 2.906.02 ± 3.206.08 ± 3.00
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir MarboxilOseltamivirTotal
Female603292
Male552681
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Baloxavir MarboxilOseltamivirTotal
American Indian or Alaska Native101
Asian101
Black or African American6511
Native Hawaiian or other Pacific Islander011
White9851149
Multiple404
Unknown516
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Baloxavir MarboxilOseltamivirTotal
Hispanic or Latino522779
Not Hispanic or Latino633194
08

Study locations

37 sites
  • Central Alabama Research; Pediatrics
    Birmingham, Alabama 35209, United States
  • Harrisburg Family Medical Center
    Harrisburg, Arkansas 72432, United States
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • The Probe Medical Research
    Los Angeles, California 90004, United States
  • Orange County Research Institute
    Ontario, California 91762, United States
  • Khruz Biotechnology Research Institute
    San Diego, California 92102, United States
  • Avanza Medical Research Center
    Pensacola, Florida 32503, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Cotton O'Neil Clinic; Stormont-Vail Hlth Care
    Topeka, Kansas 66606, United States
  • Kentucky Pediatric Research Center
    Bardstown, Kentucky 40004, United States
  • Spiegel, Craig
    Bridgeton, Missouri 63044, United States
  • Meridian Clinical Research, Llc
    Omaha, Nebraska 68134, United States
  • Machuca Family Medicine
    Las Vegas, Nevada 89104, United States
  • OnSite Clinical Solutions LLC
    Charlotte, North Carolina 28203, United States
  • Montgomery Medical Research /Frontier Clinical Research
    Smithfield, North Carolina 15478, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • AFC Urgent Care- Cleveland
    Cleveland, Tennessee 37312, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Oak Cliff Research Company, LLC
    Dallas, Texas 75243, United States
  • HD Research Corp
    Houston, Texas 77004, United States
  • Mercury Clinical Research
    Houston, Texas 77036-3316, United States
  • Tekton Research
    San Antonio, Texas 78240, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • ClinPoint Trials
    Waxahachie, Texas 75165, United States
  • FirstMed East (J Lewis Research)
    Salt Lake City, Utah 84121, United States
  • Advanced Clinical Research - Jordan Ridge Family Medicine
    Salt Lake City, Utah 84123, United States
  • ICIMED Instituto de Investigación en Ciencias Médicas
    San Jose, 10108, Costa Rica
  • Clalit Health Services- Pediatric Ambulatory Clinic; Pediatric Ambulatory Clinic
    Petach Tikva, 4931807, Israel
  • Hospital San Jose; Centro de investigacion y transferencia en salud del Tec de Monterrey
    Monterrey, N.L, 64710, Mexico
  • Wojewodzki Szpital Obserwacyjno-Zakazny; Oddział Pediatrii, Chorób Infekcyjnych i Hepatologii
    Bydgoszcz, 85-030, Poland
  • NZOZ Vitamed
    Bydgoszcz, 85-079, Poland
  • Prywatny Gabinet Lekarski
    Debica, 39-200, Poland
  • NZLA Michalkowice Jarosz i partnerzy Spolka Lekarska
    Siemianowice Śląskie, 41-103, Poland
  • MC Gepatolog
    Samara, 443100, Russian Federation
  • Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría
    Santiago de Compostela, LA Coruña 15706, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Pediatria
    Madrid, 28041, Spain
09

References and documents

Publications

  • Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 Aug;39(8):700-705. doi: 10.1097/INF.0000000000002747. PubMed 32516282 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2019, 4 months.

Results were first posted in Apr 2020, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Aug 14, 2018
StartActual
Nov 20, 2018
Primary completionActual
Apr 3, 2019
CompletionActual
Apr 3, 2019
Results first posted
Apr 29, 2020
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03629184
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Nov 20, 2018
Primary completion
Apr 3, 2019
Completion
Apr 3, 2019
Results posted
Apr 29, 2020
Last update
Apr 29, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion